1.595

5.62% -0.095

Acrivon Therapeutics Inc (ACRV)

Overview News Price History Financials Discussions Forecast

Acrivon Therapeutics Inc stock is traded at $1.595, with a volume of 700.85K. It is down -5.62% in the last 24 hours and down -0.31% over the past month. Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Previous Close:

$1.69

Open:

$1.615

24h Volume:

700.85K

Relative Volume:

0.44

Market Cap:

$50.33M

Revenue:

Net Income/Loss:

$-69.00M

P/E Ratio:

-0.5737

EPS:

-2.78

Net Cash Flow:

$-55.26M

1W Performance:

-13.32%

1M Performance:

-0.31%

6M Performance:

+19.92%

1Y Performance:

-71.42%

1-Day Range:

$1.565

$1.65

1-Week Range:

$1.415

$1.79

52-Week Range:

$1.05

$5.68

Acrivon Therapeutics Inc Stock (ACRV) Company Profile

Name

Acrivon Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

617-207-8979

Address

480 ARSENAL WAY, SUITE 100, WATERTOWN

Employee

Twitter

Next Earnings Date

2025-08-08

Latest SEC Filings

ACRV's Discussions on Twitter

Compare ACRV vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACRV Acrivon Therapeutics Inc	1.595	53.33M	0	-69.00M	-55.26M	-2.78
VRTX Vertex Pharmaceuticals Inc	459.70	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	762.45	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	721.77	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.03	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	291.37	33.09B	5.36B	287.73M	924.18M	2.5229

Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-05-25	Resumed	Piper Sandler	Overweight
Jan-31-25	Initiated	KeyBanc Capital Markets	Overweight
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy
Apr-29-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-01-24	Initiated	JMP Securities	Mkt Outperform
Dec-15-23	Resumed	Jefferies	Buy
Oct-05-23	Initiated	Maxim Group	Buy
Jun-02-23	Initiated	Oppenheimer	Outperform
May-08-23	Initiated	BMO Capital Markets	Outperform
Apr-27-23	Initiated	Ladenburg Thalmann	Buy
Apr-20-23	Initiated	H.C. Wainwright	Buy
Dec-12-22	Initiated	Cowen	Outperform
Dec-12-22	Initiated	Jefferies	Buy
Dec-12-22	Initiated	Piper Sandler	Overweight

View All

Acrivon Therapeutics Inc Stock (ACRV) Latest News

Mar 03, 2026

Acrivon Therapeutics (ACRV) CAO awarded 31,900 stock options at $0.00 strike - Stock Titan

Mar 03, 2026

Acrivon Therapeutics (ACRV) CMO granted stock options on 174,068 shares - Stock Titan

Mar 03, 2026

Executive Mary Miller at Acrivon Therapeutics (ACRV) granted 129,760 options - Stock Titan

Mar 03, 2026

Acrivon Therapeutics (ACRV) CDO awarded option on 94,946 shares - Stock Titan

Mar 03, 2026

Acrivon Therapeutics (ACRV) COO receives 186,728 stock options vesting from 2027 - Stock Titan

Mar 03, 2026

Jefferies reiterates Acrivon Therapeutics stock rating on trial data By Investing.com - Investing.com Canada

Mar 02, 2026

Jefferies reiterates Acrivon Therapeutics stock rating on trial data - Investing.com

Mar 02, 2026

Acrivon Therapeutics (NASDAQ: ACRV) takes full control of ACR-368 OncoSignature - Stock Titan

Mar 02, 2026

Feb 27, 2026